Adlai Nortye Advances First-in-Class Pan-RAS ADC AN4035 into Phase I Trial
ANL has more than doubled off its 52-week low of $0.879.
Summary
Adlai Nortye received HREC approval and submitted a CTN to initiate a Phase I trial of AN4035, a first-in-class pan-RAS(ON) inhibitor ADC, in Australia. IND submissions to the U.S. FDA and China NMPA are underway. This marks the company's second pan-RAS program entering the clinic, following the July 17 dosing of the first patient in the AN902 Phase 1 weekly arm. AN4035 targets a high-value oncology pathway with no approved therapies, and advancing it into human trials is a material pipeline milestone for a $520M market cap biotech. The trial start de-risks the program and could attract partnership interest, though efficacy data is still distant.
At the time of this announcement, ANL was trading at $13.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $520M. The 52-week trading range was $0.88 to $17.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.